Mira Pharma Financials
This page shows Mira Pharma (MIRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A development-stage model is funded by external capital while losses persist and operating cash generation remains absent
FY2025 operating cash outflow was$4.7M , while net loss was-$10.4M , showing that accounting losses and cash use reflect different pressures. Financing supplied$8.2M during FY2025, indicating the operating model still depends on external capital rather than internally generated cash.
Equity moved from
The cost structure shifted toward overhead: SG&A reached
Financial Health Signals
Mira Pharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Mira Pharma passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Mira Pharma reported a net loss of $10.4M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Mira Pharma reported -$10.4M in net income in fiscal year 2025. This represents a decrease of 33.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Mira Pharma held $6.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Mira Pharma's ROE was -100.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 256.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Mira Pharma invested $1.7M in research and development in fiscal year 2025. This represents a decrease of 48.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
MIRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $1.7M-48.0% | $3.3M+110.1% | $1.6M-33.1% | $2.4M |
| SG&A Expenses | N/A | $8.8M+86.2% | $4.7M-27.5% | $6.5M+117.2% | $3.0M |
| Interest Expense | N/A | $99K+159.7% | -$166K-104.8% | $3.5M+33619.9% | $10K |
| Net Income | N/A | -$10.4M-33.0% | -$7.9M+34.5% | -$12.0M | N/A |
| EPS (Diluted) | — | -$1.35 | -$0.51+40.0% | -$0.85-112.5% | -$0.40 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MIRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $11.1M+279.5% | $2.9M-40.7% | $4.9M+474.8% | $858K |
| Current Assets | $11.1M+282.9% | $2.9M-40.6% | $4.9M+882.6% | $494K |
| Cash & Equivalents | $6.3M+124.0% | $2.8M-38.4% | $4.6M+1211.4% | $351K |
| Accounts Receivable | N/A | $5K0.0% | $5K | N/A |
| Total Liabilities | $702K-2.9% | $723K+29.6% | $558K-61.6% | $1.5M |
| Current Liabilities | $702K-2.9% | $723K+29.6% | $558K-59.3% | $1.4M |
| Total Equity | $10.4M+372.4% | $2.2M-49.7% | $4.4M+833.7% | -$596K |
| Retained Earnings | -$39.6M-35.8% | -$29.1M-36.9% | -$21.3M-128.8% | -$9.3M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
MIRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.6M | -$4.7M+16.2% | -$5.6M-22.7% | -$4.5M | N/A |
| Financing Cash Flow | $7.5M | $8.2M+115.7% | $3.8M-56.8% | $8.8M+179.2% | $3.1M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MIRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Equity | -100.5%+256.5pp | -357.0%-83.1pp | -273.9% | N/A |
| Return on Assets | -94.1%+174.5pp | -268.6%-25.7pp | -242.9% | N/A |
| Current Ratio | 15.75+11.8x | 3.99-4.7x | 8.71+8.3x | 0.36 |
| Debt-to-Equity | 0.07-0.3x | 0.33+0.2x | 0.13 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Mira Pharma Ranks
Frequently Asked Questions
Is Mira Pharma profitable?
No, Mira Pharma (MIRA) reported a net income of -$10.4M in fiscal year 2025.
What is Mira Pharma's return on equity (ROE)?
Mira Pharma (MIRA) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mira Pharma's operating cash flow?
Mira Pharma (MIRA) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Mira Pharma's total assets?
Mira Pharma (MIRA) had $11.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Mira Pharma spend on research and development?
Mira Pharma (MIRA) invested $1.7M in research and development during fiscal year 2025.
What is Mira Pharma's current ratio?
Mira Pharma (MIRA) had a current ratio of 15.75 as of fiscal year 2025, which is generally considered healthy.
What is Mira Pharma's debt-to-equity ratio?
Mira Pharma (MIRA) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mira Pharma's return on assets (ROA)?
Mira Pharma (MIRA) had a return on assets of -94.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Mira Pharma's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Mira Pharma (MIRA) held $11.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.7M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Mira Pharma's Piotroski F-Score?
Mira Pharma (MIRA) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mira Pharma's earnings high quality?
Mira Pharma (MIRA) reported a net loss of $10.4M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.